
Appu Rathinavelu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/909451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of antitumor effects of VEGFR-2 inhibitor F16Âin a colorectal xenograft model. Biotechnology Letters, 2022, 44, 787-801.	2.2	1
2	Evaluation of anti-angiogenic agent F16 for targeting glioblastoma xenograft tumors. Cancer Genetics, 2022, 264-265, 71-89.	0.4	1
3	Effect of the HDAC Inhibitor on Histone Acetylation and Methyltransferases in A2780 Ovarian Cancer Cells. Medicina (Lithuania), 2021, 57, 456.	2.0	4
4	Molecular mechanism of C-phycocyanin induced apoptosis in LNCaP cells. Bioorganic and Medicinal Chemistry, 2020, 28, 115272.	3.0	15
5	Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways. Cellular Signalling, 2020, 66, 109435.	3.6	13
6	Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells. Cellular Signalling, 2020, 75, 109742.	3.6	6
7	The apoptotic effect of GSK-3 inhibitors: BIO and CHIR 98014 on H1975 lung cancer cells through ROS generation and mitochondrial dysfunction. Biotechnology Letters, 2020, 42, 1351-1368.	2.2	4
8	Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells. Medicina (Lithuania), 2019, 55, 30.	2.0	18
9	Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells. Cells, 2019, 8, 8.	4.1	32
10	Matrix Metalloproteinases: A challenging paradigm of cancer management. Seminars in Cancer Biology, 2019, 56, 100-115.	9.6	169
11	Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models. Oncology Reports, 2018, 39, 1711-1724.	2.6	2
12	MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells. Cells, 2018, 7, 41.	4.1	22
13	Comparative Effects of HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in LNCaP Prostate Cancer Cells. Biomedical Journal of Scientific & Technical Research, 2018, 8, .	0.1	1
14	Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor. Tumor Biology, 2017, 39, 101042831772684.	1.8	12
15	Abstract 195: Evaluation of the cell surface binding of phycocyanin and associated mechanisms causing cell death in prostate cancer cells. , 2017, , .		1
16	Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions. , 2016, , .		0
17	Apoptosis Induction byOcimum sanctumExtract in LNCaP Prostate Cancer Cells. Journal of Medicinal Food, 2015, 18, 776-785.	1.5	20
18	Abstract 5318: Effect of C-phycocyanin on the anticancer properties of taxol and topotecan in lung cancer implanted athymic nude mice. , 2015, , .		1

Appu Rathinavelu

#	Article	IF	CITATIONS
19	Abstract 80: Analysis of the regulation of angiogenesis pathway by inhibiting MDM2 function in LNCaP-MST prostate cancer cells using PCR array. , 2015, , .		2
20	Pro-angiogenic effects of MDM2 through HIF-1α and NF-κB mediated mechanisms in LNCaP prostate cancer cells. Molecular Biology Reports, 2014, 41, 5533-5541.	2.3	8
21	Induction of Apoptosis in HeLa Cells via Caspase Activation by Resveratrol and Genistein. Journal of Medicinal Food, 2013, 16, 139-146.	1.5	48
22	Activation of the intrinsic-apoptotic pathway in LNCaP prostate cancer cells by genistein- topotecan combination treatments. Functional Foods in Health and Disease, 2013, 3, 66.	0.6	2
23	A novel regulation of VEGF expression by HIFâ€lα and STAT3 in HDM2 transfected prostate cancer cells. Journal of Cellular and Molecular Medicine, 2012, 16, 1750-1757.	3.6	24
24	Anticancer activities of genisteinâ€ŧopotecan combination in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2012, 16, 2631-2636.	3.6	46
25	Phycocyanin Induces Apoptosis and Enhances the Effect of Topotecan on Prostate Cell Line LNCaP. Journal of Medicinal Food, 2012, 15, 1091-1095.	1.5	68
26	Bromelain-Induced Apoptosis in GI-101A Breast Cancer Cells. Journal of Medicinal Food, 2012, 15, 344-349.	1.5	48
27	The Effects of the Herbal Enzyme Bromelain Against Breast Cancer Cell Line GI101A. FASEB Journal, 2009, 23, LB18.	0.5	8
28	Identification of HDM2 as a regulator of VEGF expression in cancer cells. Life Sciences, 2008, 82, 1231-1241.	4.3	10
29	Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression. Life Sciences, 2007, 81, 1362-1372.	4.3	11
30	Identification of novel angiogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4125-4129.	2.2	10
31	Liquid Chromatographic Method with Electrochemical Detection for Determination of Cisapride in Serum. Journal of AOAC INTERNATIONAL, 2001, 84, 9-12.	1.5	2
32	REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION BY AP-1 PROMOTER PATHWAY. Biochemical Society Transactions, 2000, 28, A237-A237.	3.4	0
33	Expression of Vascular Endothelial Growth Factor mRNA in GI-101A and HL-60 Cell Lines. Biochemical and Biophysical Research Communications, 2000, 270, 709-713.	2.1	10